Agomab Therapeutics NV (AGMB) Price Prediction & ForecastAGMBAgomab Therapeutics NV

Alphio's AGMB stock price prediction model matches the current Agomab Therapeutics NV tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $14.73 (-0.66%). The 1-week path is $14.70 (-0.91%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Agomab Therapeutics appears to be a good buy right now due to its promising clinical developments and strong analyst support. The stock is currently priced at $13.17, significantly below the average analyst price target of $43.33, indicating substantial upside potential. Additionally, the recent initiation of a Phase 2b trial for its drug Ontunisertib in Crohn's disease aligns with a growing market projected to reach $13.20 billion by 2023, further enhancing its growth prospects. However, the company reported a negative EPS of -0.71 for Q3 2024, which is a risk to consider.

Agomab Therapeutics NV (AGMB) last closed at $14.83, gaining +8.57%. These facts feed the 1-day and 1-week AGMB price prediction above.